166 related articles for article (PubMed ID: 27650585)
1. Recombinant canstatin inhibits VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-VII animal model.
Hwang-Bo J; Park JH; Bae MG; Chung IS
Cancer Med; 2016 Oct; 5(10):2977-2988. PubMed ID: 27650585
[TBL] [Abstract][Full Text] [Related]
2. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
Hwang-Bo J; Bae MG; Park JH; Chung IS
BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
[TBL] [Abstract][Full Text] [Related]
3. Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis.
Hwang-Bo J; Yoo KH; Park JH; Jeong HS; Chung IS
Int J Cancer; 2012 Jul; 131(2):298-309. PubMed ID: 21823121
[TBL] [Abstract][Full Text] [Related]
4. Effects of 6,8-Diprenylgenistein on VEGF-A-Induced Lymphangiogenesis and Lymph Node Metastasis in an Oral Cancer Sentinel Lymph Node Animal Model.
Bae MG; Hwang-Bo J; Lee DY; Lee YH; Chung IS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466636
[TBL] [Abstract][Full Text] [Related]
5. Recombinant canstatin inhibits tumor growth in an orthotopic AT-84 oral squamous cell carcinoma model.
Hwang-Bo J; Yoo KH; Jeong HS; Chung IS
Biotechnol Lett; 2010 Feb; 32(2):189-94. PubMed ID: 19838634
[TBL] [Abstract][Full Text] [Related]
6. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
7. WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells.
Lin CC; Chen PC; Lein MY; Tsao CW; Huang CC; Wang SW; Tang CH; Tung KC
Oncotarget; 2016 Mar; 7(9):9993-10005. PubMed ID: 26824419
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
9. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.
Pajares MJ; Agorreta J; Larrayoz M; Vesin A; Ezponda T; Zudaire I; Torre W; Lozano MD; Brambilla E; Brambilla C; Wistuba II; Behrens C; Timsit JF; Pio R; Field JK; Montuenga LM
J Clin Oncol; 2012 Apr; 30(10):1129-36. PubMed ID: 22355056
[TBL] [Abstract][Full Text] [Related]
10. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
11. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
13. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma.
Shinriki S; Jono H; Ueda M; Ota K; Ota T; Sueyoshi T; Oike Y; Ibusuki M; Hiraki A; Nakayama H; Shinohara M; Ando Y
J Pathol; 2011 Sep; 225(1):142-50. PubMed ID: 21710490
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory effect of endostar on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells].
Shang L; Zhao J; Wang W; Xiao W; Li J; Li X; Song W; Liu J; Wen F; Yue C
Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):722-9. PubMed ID: 25342038
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma.
Liang X; Yang D; Hu J; Hao X; Gao J; Mao Z
Anticancer Res; 2008; 28(3A):1659-66. PubMed ID: 18630523
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
Kobayashi S; Kishimoto T; Kamata S; Otsuka M; Miyazaki M; Ishikura H
Cancer Sci; 2007 May; 98(5):726-33. PubMed ID: 17425689
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
20. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis.
Ohno F; Nakanishi H; Abe A; Seki Y; Kinoshita A; Hasegawa Y; Tatematsu M; Kurita K
J Oral Pathol Med; 2007 May; 36(5):281-9. PubMed ID: 17448138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
